Table 5.
Baseline PET/CT: LPR P-P of different subgroups related to PSA subgroups.
| PSA Range (ng/mL) | Overall Positivity | Chi2p/r Value | Single Metastases | Multiple Metastases | Chi2p/r Value | |||
| 0.2 to <1 (58) | 17 (29.3%) | 9 (15.5%) | 6 (10.3%) | |||||
| <1.24 (71) | 24 (33.8%) | 12 (16.9%) | 9 (12.7%) | |||||
| ≥1.24 (107) | 90 (84.1%) | 13 (12.1%) | 69 (64.5%) | |||||
| Total (178) | 114 (64%) |
p < 0.001 r 0.513 |
25 | 78 |
p < 0.001 r 0.522 |
|||
| PSA Range (ng/mL) | Local Recurrence | p/r Value | Local Metastases | Distant Metastases | Local + Distant Metastases | p/r Value | ||
| 0.2 to <1 (58) | 2 (3.4%) | 8 (13.8%) | 4 (6.9%) | 3 (5.2%) | ||||
| <1.24 (71) | 3 (4.2%) | 9 (12.7%) | 7 (9.9%) | 5 (7.0%) | ||||
| ≥1.24 (107) | 24 (22.4%) | 31 (29.0%) | 24 (22.4%) | 27 (25.2%) | ||||
| Total (178) | 27 |
p = 0.001 r 0.249 |
40 | 31 | 32 |
p < 0.001 r 0.412 |
||
Abbreviations: PSA, prostate-specific-antigen; p < 0.05 is considered significant; r, Pearson correlation coefficient.